Stemina Biomarker Discovery has pioneered building human cellular models for toxicity screening of drug candidates, chemical compounds, and cosmetic and tobacco ingredients. Our in vitro toxicity assays offer an alternative to animal tests that are highly predictive of human response using human cell-based endpoints and very little test compound. These assays can provide data in only a few weeks at a fraction of the cost of animal testing.
“[Stemina] provides a key platform in support of EPA’s ToxCast and Virtual Tissue Model programs, including an assay on human embryonic stem cell metabolism that is highly unique … as they specialize in metabolomics profiling. [Stemina] consistently exceeded performance expectations and successfully delivered timely, high-quality, responsive services and products.”
Cardio quickPredictTM indicates the cardiotoxicity potential of drug candidates and other lead compounds based on changes in human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) metabolism and viability.
Stemina Biomarker Discovery is one remarkable corporation with two distinct business units: Stemina is focused on toxicology, NeuroPointDX is focused on diagnosis and treatment of neurological disorders such as autism.